161 related articles for article (PubMed ID: 37643043)
1. PRESUMPTIVE RECURRENCE OF INTRAOCULAR LYMPHOMA DESPITE CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY.
Taher A; Abadir E; McCluskey P; Hamad N; Lo TH; Heydon P
Retin Cases Brief Rep; 2023 Sep; 17(5):562-566. PubMed ID: 37643043
[TBL] [Abstract][Full Text] [Related]
2. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
4. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: A case report and review of the literature.
Gao S; Zhou Y; Jin X; Lin Z; Zhong Y; Shen X
Surv Ophthalmol; 2019; 64(2):225-232. PubMed ID: 30321569
[TBL] [Abstract][Full Text] [Related]
5. AN UNUSUAL CASE OF PRIMARY VITREORETINAL LYMPHOMA: A TRANSFORMED LYMPHOMA.
Ustaoglu M; Patel R; Wang W; Shah S; Barr C
Retin Cases Brief Rep; 2024 Mar; 18(2):181-183. PubMed ID: 36730965
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
7. CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy.
Matsuo T; Tanaka T; Fujii N; Fujii K; Kondo E
J Clin Exp Hematop; 2022 Sep; 62(3):187-189. PubMed ID: 35732410
[No Abstract] [Full Text] [Related]
8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
9. First observation of intraocular extranodal natural killer/T-cell lymphoma secondary to a retroperitoneal tumour: a case report and comparative review.
Chen B; Yang S; Su W
BMC Ophthalmol; 2022 Mar; 22(1):141. PubMed ID: 35346113
[TBL] [Abstract][Full Text] [Related]
10. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
[TBL] [Abstract][Full Text] [Related]
11. HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens.
Albadri ST; Pulido JS; Macon WR; Garcia JJ; Salomao DR
Retina; 2020 Feb; 40(2):391-398. PubMed ID: 31972811
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
15. Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.
Sheng L; Zhang Y; Song Q; Jiang X; Cao W; Li L; Yi H; Weng X; Chen S; Wang Z; Wu W; Wang L; Zhao W; Yan Z
Front Immunol; 2023; 14():1298815. PubMed ID: 38173731
[TBL] [Abstract][Full Text] [Related]
16. Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma.
Zhu H; Zhuang Z; Wang W; Zhao D; Zhang W; Zhou D; Zhang Y
Eur J Haematol; 2024 Feb; 112(2):310-313. PubMed ID: 37723652
[TBL] [Abstract][Full Text] [Related]
17. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
Sun Z; Xie C; Liu H; Yuan X
Front Immunol; 2022; 13():778192. PubMed ID: 35154102
[TBL] [Abstract][Full Text] [Related]
18. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell therapy in large B cell lymphoma.
Boardman AP; Salles G
Hematol Oncol; 2023 Jun; 41 Suppl 1(Suppl 1):112-118. PubMed ID: 37294963
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
